Abbott Stock Surges 11% After Q2 Earnings Beat and Full-Year Guidance Raise

Key Facts

In a move reflecting strong operational performance in the med-tech sector, Abbott Laboratories raised its annual profit forecast for 2026 after posting quarterly results that exceeded estimates. The company reported adjusted earnings per share (EPS) of $1.31, surpassing the consensus estimate of $1.28. This upward revision is driven by robust and sustained demand for its cardiovascular medical devices, signaling management's confidence in maintaining growth momentum.

This outperformance comes amid intensifying competition from peers such as Medtronic and Boston Scientific, which have also reported significant growth in cardiovascular sales. Per market data, improved supply chains and a global rise in elective medical procedures have bolstered profit margins across the industry. Investors reacted strongly to the news, driving Abbott's share price up by approximately 11% following the announcement.

In the markets, ABT stock stood at $89.27 (at close July 16, 2026) following the surge, up from the previous close of $89.27. Investors are now looking ahead to the Federal Reserve's Monetary Policy Report, as it may directly impact financing costs and valuations within the biotechnology and healthcare sectors.